Skip to main content
Premium Trial:

Request an Annual Quote

This Week in Science: Jan 5, 2013

In Science this week, two new studies describe the use of the prokaryotic CRISPR adaptive immune system for editing mammalian genomes, suggesting that approach could be a tool for deleting or revising genes simultaneously at several sites on the genome. In the first report, Broad Institute researchers detail how they engineered two CRISPR systems to show that Cas9 nucleases can be directed by short RNAs to induce precise cleavage at endogenous genomic loci in both human and mouse cells. In the second paper, a Harvard Medical School team shows that CRISPR-mediated genome editing can be used on a variety of human cell lines, including induced pluripotent stem cells, and that the method offers advantages over TALEN-based editing systems.

Daily Scan's sister publication GenomeWeb Daily News has more on these studies here.

Over in Science Translational Medicine, researchers from Denmark report on their development of Yucatan minipigs that overexpresses human D374Y-PCSK9 in their livers. The model, they add, "developed severe hypercholesterolemia and human-like progressive atherosclerotic lesions on a HFHC diet and may be used for translational research in imaging technologies, intravascular devices, life-style factors, and drug therapy."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more